Value202020212022202320242025TTMSelling/general/admin expenses———144.5 M155.78 M165.41 M165.41 MResearch & development———163.54 M222.15 M274.87 M274.87 MOperating income———-59.65 M-70.46 M-45.35 M-45.35 MNon-Operating Income, Total———3.91 M36.37 M38.42 M38.42 MInterest expense, net of interest capitalized———5.15 M18.84 M12.17 M12.17 MNon-Operating Income, excl. Interest Expenses———-344 K3.33 M6.53 M6.53 MUnusual income/expense———-897 K14.2 M19.73 M19.73 MPretax income———-60.89 M-52.94 M-19.1 M-19.1 MEquity in earnings———————Taxes———-5.6 M-1.85 M16.41 M16.41 MNon-controlling/minority interest———————After tax other income/expense———-412 K-1.84 M-2.11 M-2.11 MNet income before discontinued operations———-55.29 M-51.09 M-35.51 M-35.51 MDiscontinued operations———————Net income———-55.29 M-51.09 M-35.51 M-35.51 MDilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders———-55.29 M-51.09 M-35.51 M-35.51 MBasic earnings per share (Basic EPS)———-1.13-1.02-0.71-0.71Diluted earnings per share (Diluted EPS)———-1.13-1.02-0.71-0.71Average basic shares outstanding———48.89 M49.99 M50.35 M201.13 MDiluted shares outstanding———48.89 M49.99 M50.35 M202.99 MEBITDA———-55.55 M-66.26 M-42.25 M-42.09 MEBIT———-59.65 M-70.46 M-45.35 M-45.35 MCost of revenue———1.04 M2.73 M5.09 M5.09 MOther cost of goods sold———————Depreciation & amortization (cash flow)———4.1 M4.2 M3.1 M3.27 M
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.